Abstract
Traditional paradigms frame celiac disease onset as a localized enteropathy, strictly isolated to the intestinal mucosa, and treat associated hepatic anomalies as secondary, downstream consequences of untreated disease. However, classic metabolic frameworks first established in 1979 demonstrated that peripheral, non-hepatic inflammatory insults, ranging from adjuvant-induced polyarthritis to thermal/scald trauma, induce a profound transcriptomic and cellular reprogramming of hepatic priorities. This Hepatic Acute-Phase Response is marked by severe transcriptional suppression of microsomal Cytochrome P450 drug-metabolizing enzymes, but concurrent mobilization of protective, cytosolic enzymes like alcohol dehydrogenase (ADH) to combat localized oxidative tissue stress. Expanding upon our 2026 "inflammatory load" framework describing onset of celiac disease, the transition from asymptomatic genetic susceptibility to active, autoimmune duodenal tissue destruction is proposed to be driven by a self-amplifying, bidirectional feedback loop between duodenum and liver. Under this model, the liver acts as an upstream instigator and dynamic amplifier of the intestinal immune response, rather than a passive bystander. Initial localized duodenal barrier breakdown (i.e., leaky gut) permits uncontrolled influx of macromolecular fragments, specifically Gram-negative bacterial lipopolysaccharide, into the portal vein. Upon sensing portal endotoxemia, the liver undergoes acute-phase response, actively diverting its functional priorities. The resulting hepatic backlash triggers a multi-pronged assault onto the duodenal mucosa. There are two primary anatomical pathways: 1. The transcriptional suppression of hepatic nuclear receptors alters bile acid synthesis and conjugation, unleashing a cytotoxic secondary bile pool via the common bile duct directly into the duodenal lumen, accelerating local dysbiosis. 2. The concurrent hepatic secretion of robust systemic cytokines to the basolateral membrane of enterocytes downregulates monocarboxylate transporter 1 (MCT1), paralyzing the duodenal butyrate shield to halt tight-junction repair and epithelial renewal. The highest concentrated volume of altered hepatic bile meets dietary gliadin peptides at the duodenal bulb and proximal descending duodenum; hence catastrophic loss of oral tolerance and subsequent villous atrophy concentrate there. Variations in intensity, topography, and tissue resilience of this gut-liver feedback loop offer a molecular explanation for long-standing clinical anomalies including seronegative celiac disease (due to highly localized tolerance), delayed or incomplete mucosal recovery on a gluten-free diet (caused by widespread tissue exhaustion), and refractory celiac disease (the unrecoverable, autonomous autocrine loop). To validate this paradigm and define the metabolic tipping point, we suggest that future studies utilize multi-compartment omics, including direct duodenal capsule sampling and spatial transcriptomics of biopsy tissue, to trace sequential MCT1/IAP degradation gradients.
